Quanterix (NASDAQ:QTRX – Get Free Report) and Electromedical Technologies (OTCMKTS:EMED – Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability and analyst recommendations.
Valuation and Earnings
This table compares Quanterix and Electromedical Technologies’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Quanterix||$105.52 million||9.23||-$96.70 million||($1.77)||-14.65|
Electromedical Technologies has lower revenue, but higher earnings than Quanterix.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Quanterix presently has a consensus target price of $25.00, indicating a potential downside of 3.59%. Given Quanterix’s higher probable upside, equities analysts plainly believe Quanterix is more favorable than Electromedical Technologies.
This table compares Quanterix and Electromedical Technologies’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
86.6% of Quanterix shares are held by institutional investors. Comparatively, 0.0% of Electromedical Technologies shares are held by institutional investors. 8.2% of Quanterix shares are held by insiders. Comparatively, 1.0% of Electromedical Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Quanterix beats Electromedical Technologies on 5 of the 8 factors compared between the two stocks.
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. It offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. The company also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assay kits and other consumables such as reagents. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
About Electromedical Technologies
Electromedical Technologies, Inc., a bioelectronics manufacturing and marketing company, provides medical devices for pain management in the United States. It offers WellnessPro Plus, a bioelectronics therapy prescription device that is used by consumers and health care professionals to relieve chronic and acute pain. The company also develops WellnessPro POD, a compact clinical-grade wearable device for pain management; and Wellness ION Pen, an interferential cold laser used to deliver targeted frequency stimulation to improve circulation and tissue healing, and reduce inflammation and pain. Electromedical Technologies, Inc. was founded in 2002 and is headquartered in Scottsdale, Arizona.
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.